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Abstract
Target agents are peculiar oncological drugs which differ from the traditional therapies in
their ability of recognizing specific molecules expressed by tumor cells and microenviron-
ment. Thus, their toxicity is generally lower than that associated to chemotherapy, and they
represent nowadays a new standard of care in a number of tumors. This paper deals with
the relationship between economic costs and toxicity of target agents. At this aim, a cluster
analysis-based exploration of the main features of a large collection of them is carried out,
with a specific focus on the variables leading to the identification of their toxicity and related
costs. The analysis of the toxicity is based on the Severe Adverse Events (SAE) and Discon-
tinuation (D) rates of each target agent considering data published on PubMed from 1965 to
2016 in the phase II and III studies that have led to the approval of these drugs for cancer
patients by US Food and Drug Administration. The construction of the dataset represents a
key step of the research, and is grounded on the critical analysis of a wide set of clinical
studies. In order to capture different evaluation strategies of the toxicity, clustering is per-
formed according to three different criteria (including Voronoi tessellation). Our procedure
allows us to identify 5 different groups of target agents pooled by similar SAE and D rates
and, at the same time, 3 groups based on target agents’ costs for 1 month and for the
median whole duration of therapy. Results highlight several specific regularities for toxicity
and costs. This study present several limitations, being realized starting from clinical trials
and not from individual patients’ data. However, a macroscopic perspective suggests that
costs are rather heterogeneous, and they do not clearly follow the clustering based on SAE
and D rates.
Introduction
The present study aims at finding out whether there is a clear connection between the toxicity
of novel anticancer drugs and their cost. To this end, we explore the information related to the
rate of Severe Adverse Events (SAE) and the discontinuation (D) of a qualified set of oncologi-
cal drugs. Such rates contribute to the creation of a so-called Toxicity Index (TI). Specifically,
we have created a high-quality dataset by investigating the phase III studies in the context of
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the approval by the US Food and Drug Administration (FDA) of the target agents and of their
introduction in the clinical practice.
The motivations for our study are of economic and social nature. In fact, cancer is one of
the most costly health conditions to manage worldwide [1]. Anticancer agents have repre-
sented the 43% of new drugs approved by the FDA in the last decade [2]. The increase of drug
spending in oncology is mainly due to the recent introduction of new targeted and immuno-
therapy agents [3], which have improved the outcome of cancer patients in terms of Overall
Survival (OS) and Progression-Free Survival (PFS) compared to conventional chemotherapy.
Although these agents are generally associated with a lower rate of treatment D due to drug
toxicity, their impact on patients’ Quality of Life (QoL) should not be overlooked. Improving
patients’ QoL and their compliance to treatments will represent the challenge for cancer
researchers in the future years. Indeed, by a purely economic perspective, reducing the toxic
effects of these treatments will allow to decrease the abstention from work days and to increase
productivity, hence leading to a wider access to cures due to a better economic status [4–8].
This paper can be properly inserted in the frame of pharmacoeconomics, which is a scien-
tific discipline related to the cost and the value of drugs and provides suggestion for the opti-
mal allocation of the healh care resources. This conceptualization was proposed by Townsend
in 1987 [9], who identified the Pharmacoeconomics as “the description and the analysis of
costs of therapeutic approch substained by the Health System and Society”. However, the first
definition of Pharmacoeconomics dates back to 1977 when Weinstein and Stason [10] pub-
lished a paper dealing with economic analysis in health field.
On the current scenario of rapidly rising health care costs, pharmaeconomic techniques are
becoming increasingly relevant to analyze the cost-effectiveness and economic sustainability
of emerging drugs [11]. Among such techniques, cluster analysis plays a relevant role. In fact,
cluster analysis is used to identify groups of similar data based on selected variables and is par-
ticularly suitable for their comparison. The versatility of such a statistical technique explains
also its popularity in many fields of applied science [12–20]. Indeed, cluster analysis seems to
be appropiate for performing a global study of the connection between drug effectiveness, tox-
icity and cost. In this context, it is worth mentioning Perrier et al [14], who explored the trans-
ferability of health cost assessment between Italy and France. The authors constructed a
hierarchical structure using cluster analysis and identified four different clusters based on
diagnosis, surgery, chemotherapy and follow-up. Their findings showed that a high variability
was present between this two countries, suggesting a low transferability of cost evaluations
across Italy and France. Two years later, Liao et al. [15] performed an observational study on
18,380 patients with end-stage renal disease who initiated hemodialysis. By using K-means
and hierarchical cluster analyses with either flexible beta or Ward’s methods, they identified 4
clusters based on sample sizes and change of cost patterns, finding that higher costs were cor-
related with more increasing comorbidity scores.
In our study we are different from the quoted papers since we first create a dataset containing
clinical and economic information about all the oncological target agents approved in clinical prac-
tice. In this respect, it is important to recall that a target agent is a drug that is able to recognize one
or more specific molecules expressed by tumor cells, immune cells or, more generally, by tumor
microenvironment in cancer patients. The identification procedure has been rather complex -it
mirrors the complexity of the faced problem- and represents a relevant step of the research.
Furthermore, we have employed a method based on Voronoi tessellation [21], which repre-
sents a potential visualization of the subgroups identified by the cluster analysis. Voronoi dia-
gram is a kind of decomposition of a given metric space based on the distance (which is
Euclidean in the original formulation of Voronoi) to specified sites called centroids [21]. Par-
ticularly, each centroid recognizes data that are nearer to it than to the other centroids in
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accord to the given distance. By applying this technique, we are able to explore the way in
which clusters of toxicity and costs overlap, hence giving information on the relationship
between drug toxicity and related cost.
As we will see below, to gain more insights we depart from the original formulation of Vor-
onoi and consider also minimum and maximum distances.
Cluster analysis, with a specific Voronoi diagrams approach, has been recently applied in
the economic field [22–25]. In 2009, Liu et al. [22] explored the distribution of rural assess-
ment using this technique. They showed that the distance from highways and rivers were the
two factors that majorly influenced the distribution of rural settlements. More recently, Vaz
et al. [23] reported a significant difference in term of regional innovation patterns as a conse-
quence of istitutional innovation profiles.
As already mentioned above, we here investigate, through a cluster analysis procedure,
whether there is a correlation between the cost of molecularly targeted and immnotherapy
agents and their toxicity in terms of SAE and D rates.
To the best of our knowledge, this is the first paper dealing with toxicity and cost of target
agents in oncology through a cluster analysis. More than this, the construction of the dataset
on the basis of an exhaustive literature review is also a novelty in the oncological studies.
The rest of the paper is organized as follows. Section 2 collects the results of the analysis,
while Section 3 provides a discussion of them. In Section 4 we present how the used dataset
has been constructed and illustrate its main statistical properties. Furthermore, Section 4 con-
tains also the description of the employed methodological tools, with a detailed explanation of
the cluster analysis.
Materials and methods
Costruction of the dataset
The construction of the dataset has been implemented through a critical analysis of a wide set
of clinical studies.
The selection of the relevant researchs has been carried out according to the instructions
contained in the PRISMA [26] (S1 File). The scientific literature of interest has been identified
from keywords selections on the PubMed database, in a period ranging from 1965 to 2016.
Specifically, the research has been conducted by combining the words "cancer", "neoplasm",
"solid tumor" and "clinical trial" with the name of each target agent.
As a second step, we have identified the papers dealing with human studies and randomized
trials published in English and meeting the following criteria: 1) phase III studies conducted in
patients with cancer; 2) random assignment of participants to treatment with a target therapy
or a control (standard of care, placebo or best supportive care). In case of several publications
related to the same experiment, only the most recent one or the most complete referring to
included trial has been considered. Phase I and phase II trials has been excluded because of
their variability and the lack of sufficient controls.
For each of the obtained papers we have reported the scientific study, the name of all authors,
the name of the journal, the reference year, the number of the volume and the reference pages.
The resulting list of studies on target agents has been explored to assess the variables of
interest related to the specific agent, i.e.: number of patients treated with target agents in the
clinical studies, PFS (defined as the time from the start of therapy to disease progression or
death), rate of all-grade AE and SAE (which leads to the necessity of medical assistence, hospi-
talization or drug interruption) and the D rate due to drug toxicity.
For the present research, we consider as variables the rate of SAE and the D rate, leaving the
other ones for future studies.
Toxicity and cost of oncological target agents
PLOS ONE | https://doi.org/10.1371/journal.pone.0183639 August 22, 2017 3 / 17
Information on the costs of the target agents has been derived directly from their websites.
All costs are expressed in American US Dollars.
Cluster analysis
Cluster analysis and Voronoi tesselation were performed by R software version 3.3.0 for Win-
dows (62 megabytes, 32/64 bit). We have compared the clusters of target agents obtained when
taking toxicity and when taking costs.
For what concerns toxicity, we have considered SAE and D rates as relevant variables. They
are the parameters concurring in our conceptualization of the Toxicity Index (TI, hereafter).
The procedure of centroids selection has been implemented accordingly to clinical and sci-
entific criteria, in order to represent the most meaningful groups of combinations of the two
variables. For this analysis, we have reasonably considered five centroids as follows: ϕ1 =
(10,5); ϕ2 = (30,15); ϕ3 = (45,10); ϕ4 = (60,20); ϕ5 = (75,25), where the first component is the
SAE value while the second one represents the D rate. In particular, centroid ϕ1 is associated
with low rate of SAE and low D rate, which leads to a low TI; ϕ2 has low-medium rate of SAE
and medium D rate, which means low-medium TI; ϕ3 has medium rate of SAE and low-
medium D rate (medium TI); ϕ4 represents medium-high rate of SAE and medium-high D
rate (medium-high TI); ϕ5 identifies a cluster with high rate of SAE and high D rate (high TI).
The cluster obtained by centroid ϕh will be denoted by Ch, for each h = 1,2,3,4,5. Moreover, by
denoting the observations of SAE and D rates by the variables x and y, respectively, we also
denote components of the centroid ϕh = (ϕh,x,ϕh,y), for each h = 1,2,3,4,5.
Clusters are identified by the nearness of the target agent toxicity with the centroids. At this
aim, we apply three different concepts of distance: an Euclidean one–in accord to the original
model of Voronoi-, the maximum and the minimum. Formally, for any given target agent
j = 1,2,. . .,37 with SAE rate xj and D rate yj, we define
dEðj; hÞ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðxj   h;xÞ
2
þ ðyj   h;yÞ
2
q
dMðj; hÞ ¼ maxfjxj   h;xj; jyj   h;yjg
dmðj; hÞ ¼ minfjxj   h;xj; jyj   h;yjg
According to the specific metric selected, we derive the clusters of target agents as follows:
CKh ¼ fj ¼ 1; . . . ; 37j dKðj; hÞ < dKðj; hÞ; 8h 6¼ hg; 8 K ¼ E;M;m; 8 h ¼ 1; 2; 3; 4; 5:
For what concerns the costs of the target agents, we have implemented two simple cluster-
ings based on two variables. First, we have grouped the investigated drugs into three groups on
the basis of 1-month cost patterns: cost less than 7,000$ (Group A), cost ranging from 7,000 to
11,000$ (Group B) and cost greater than 11,000$ (Group C). In the same way, drugs were
grouped according to their costs extimated for the complete treatment for each patient within
3 groups: cost less than 40,000$ (Group D), cost ranging from 40,000$ to 80,000$ (Group E)
and cost greater than 80,000$ (Group F).
Results
At the end of text analysis, we have obtained 4,803 studies concerning the use of molecular tar-
geted drugs in cancer patients (the list of drugs is reported in the first column of Table 1).
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Table 1. List of target agents employed in oncological patients. Their characteristics are related to drug efficacy in terms of median Progression-Free
Survival (PFS) and drug toxicity in terms of rate of all-grade, severe adverse events and discontinuation rate. BCC = Basal-cell Carcinoma;
GIST = Gastrointestinal Stromal Tumor; NSCLC = Non Small Cell Lung Cancer; RCC = Renal Cell Carcinoma.
Target Agent First Authors,
Year
Reference Cancer Type Number of
Patients
Median PFS
(Months)
All grade
Adverse Events
(%)
Severe
Adverse
Events(%)
D Rate
(%)
Abiraterone acetate (first
line therapy)
Charles JR, 2013 27 Prostate 546 16.5 99 48 10
Abiraterone acetate
(successive line-therapy)
de Bono S, 2011 28 Prostate 797 5.6 23 7 19
Afatinib Sequist LV, 2013 29 NSCLC 230 11.1 NA 49 8
Bevacizumab Friedman HS,
2009
30 Glioblastoma 82 5.6 100 65.8 17.7
Bevacizumab Escudier B, 2007 31 RCC 327 10.2 97 29 28
Bevacizumab (first line
therapy)
Hurwitz H, 2004 32 Colorectal 411 10.6 NA 84,9 8.4
Bevacizumab
(successive line-therapy)
Bennouna J,
2013
33 Colorectal 409 5.7 98 64 16
Cabozantinib Eisei R, 2013 34 Thyroid 219 11.2 NA 69 16
Cetuximab Vermorken JB,
2008
35 Head and Neck 222 5.5 NA 82 20
Cobimetinib
+ Vemurafenib
Larkin J, 2014 36 Melanoma 247 9.9 95 62 12
Crizotinib Shaw AT, 2013 37 NSCLC 173 7.7 NA 33 6
Enzalutamide (first line
therapy)
Beer TM, 2015 38 Prostate 800 8.3 34 28 8
Enzalutamide
(successive line-therapy)
Scher HI, 2012 39 Prostate 872 5.7 97 43 6
Erlotinib Moore MJ, 2007 40 Pancreas 282 3.8 100 61 10
Erlotinib (first line
therapy)
Rosell R, 2012 41 NSCLC 86 9.7 98 45 13
Erlotinib (maintainance
therapy)
Cappuzzo F,
2010
42 NSCLC 438 2.9 NA 11 16
Everolimus Baselga J, 2012 43 Breast 482 7.8 NA 23 19
Lenvatinib Schlumberger M,
2015
44 Thyroid 261 14.7 97.3 75.9 14.2
Nivolumab Brahmer J, 2015 45 Squamous
NSCLC
135 3.5 58 7 3
Nivolumab Borghaei H,
2015
46 Non-Squamous
NSCLC
292 2.3 69 10 5
Nivolumab Robert C, 2015 47 Melanoma 210 5.1 74.3 11.7 2.4
Nivolumab Motzer RJ, 2015 48 RCC 410 4.6 79 19 8
Palbociclib (+letrozole) Finn RS, 2015 49 Breast 84 20.2 99 76 33
Palbociclib (+fulvestrant) Turner NC, 2015 50 Breast 347 9.2 97.7 69,3 2.6
Pembrolizumab Robert C, 2015 51 Melanoma 277 4.1 72.9 75 6.9
Ramucirumab Fuchs CS, 2014 52 Gastric 238 2.1 94 57 11
Ramucirumab Garon EB, 2014 53 NSCLC 628 4.5 98 79 15
Ramucirumab Tabernero J,
2015
54 Colorectal 536 5.7 83 36 11
Regorafenib Grothey A, 2013 55 Colorectal 505 1.9 93 54 44.8
Sonidegib Midgen MR,
2015
56 BCC 79 13.1 95 31 22
Sorafenib Escudier B, 2007 57 RCC 451 5.5 NA 34 10
Sunitinib Motzer RJ, 2009 58 RCC 375 11 NA 7 38
(Continued )
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Table 1. (Continued)
Target Agent First Authors,
Year
Reference Cancer Type Number of
Patients
Median PFS
(Months)
All grade
Adverse Events
(%)
Severe
Adverse
Events(%)
D Rate
(%)
Sunitinib Demetri GD,
2006
59 GIST 207 6.4 83 20 9
T-DM1 Verma S, 2012 60 Breast 495 9.6 95.9 15,5 5
Temsirolimus Hudes G, 2007 61 RCC 209 3.8 NA 11 7
Trametinib + Dabrafenib Long GV, 2014 62 Melanoma 211 9.3 95 32 9
Ziv-Aflibercept Van Cutsem E,
2012
63 Colorectal 612 6.9 99.2 83,5 26.8
https://doi.org/10.1371/journal.pone.0183639.t001
Fig 1. Study selection according to PRISMA statement.
https://doi.org/10.1371/journal.pone.0183639.g001
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Therefore, 2,914 of the 4,083 original papers have been excluded because of phase I studies,
observational, in vitro, reviews or letters about targeted therapies. Of the 1,889 remained stud-
ies, 1,852 were excluded because dealing with phase II or because not containing data on the
SAE and D rates.
As a result, we have found 23 target agents that are used in 37 different therapeutic settings
[27–63] (Table 1).
The identification of the relevant papers is described in Fig 1, where it is presented a block
diagram of the PRISMA procedure.
Table 2 contains the main statistical indicators of the dataset. The mean/std. dev. ratio
allows additional considerations about the heterogeneity within the clusters, which is low, sup-
porting that each cluster includes similar drugs both in terms of SAE and D rates.
Concerning skewness, it is relevant to note that only the rate of all grade adverse events is
negative (-2.06) with a curve of distribution characterized by a longer left tail with a median of
patients developing at least an adverse event (95%) that overcross the mean of patients (86%).
Further information can be added by observing the leptokurtic distribution of all grade adverse
events (curtosis is 3.95), while the distribution of SAE is platykurtic (curtosis is -1.38).
It is also important to observe the response rates reported by target agents, which range
from 1% to 80% (Table 2). Such a result underlines the extreme variety of actions of these new
generation agents that can improve patient survival without reducing tumour sizes.
Fig 2A, 2B and 2C show the clusters based on Euclidean distance, maximum distance and
minimum distance, respectively. A spatial representation of the dynamic fields related to clus-
ter analysis by Euclidean distance has been obtained by Voronoi diagram as reported in Fig 3.
The results of cluster analysis with Euclidean distance show a major similarity with the find-
ings obtained by the maximum distance. In particular, such clustering criteria place in two dif-
ferent clusters only two drugs (Regorafenib, charaterized by SAE and D rates of 54 and 44.8,
respectively, and Pembrolizumab, with SAE and D rates of 75 and 6.9, respectively. They
belong to cluster 4 based on Euclidean distance and to cluster 5 according to the maximum
distance). Differently, the clusters based on minimum distance are markedly different from
both the other analyses.
It is interesting to note that the highest cost for a month and per PFS are represented by the
combination of Cobimetinib and Vemurafenib and the lowest by Erlotinib (when used for
patients with pancreatic cancer). The mean and median montly costs are 9,366 $ and 8,627 $,
Table 2. Main statistical indicators of the dataset.
Number of patients DRUG EFFECTIVENESS DRUG TOXICITY
Median PFS (months) All grade adverse events
(%)
Severe adverse events
(%)
Discontinuation rate (%)
Mean 356 7.60 86 44 14
Std. Dev. 205 4.14 20 26 10
Mean/Std.
Dev.
1.73 1.84 4.30 1.68 1.42
Min 79 1.9 23 7 2.4
Max 872 20.2 100 84.9 45
Median 292 6.4 95 43 11
Skewness 0.83 1.03 -2.06 0.10 1.48
Kurtosis 0.23 1.21 3.95 -1.38 2.19
Q1 211 4.6 81 20 8
Q3 482 9.9 98 65.8 17.7
https://doi.org/10.1371/journal.pone.0183639.t002
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respectively. On the other hand, the mean and median costs per PFS are 73,154 $ and 49,500 $,
respectively (Table 3).
Fig 2. Cluster analysis based on Toxicity Index (TI) considering Euclidean distance (A), maximum distance
(B) and minimum distance (C). The “+” represent the centroids.
https://doi.org/10.1371/journal.pone.0183639.g002
Toxicity and cost of oncological target agents
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Both Fig 4A and 4B show that heterogeneous cost distribution that doesn’t clearly follow
the cluster division based on TI. However, some illustrations of the relationship between toxic-
ity and costs can be carried out at the single clusters level. For instance, as for the 1-month
cost, the higher rate of drugs from Group C belongs to Cluster 5, whilst the higher percentage
of drugs from Group A are included in Cluster 3. Concerning the total cost estimated for a sin-
gle patient for the whole treatment, the higher rate of drugs belonging to Group D belongs to
Cluster 4, whilst the higher percentage of drugs from Group F are in Cluster 5. The complete
distribution of costs within the 5 clusters is reported in Table 4 and Fig 5.
Discussion
Our paper concerns the study of the relationship between the toxicity and cost of newly
approved target agents in the Oncology field. All the drugs approved by FDA have been con-
sidered. Variables related to SAE and D rates have been collected from published phase III
studies.
Cluster analysis has been employed to explore such a relationship. Specifically, three differ-
ent clustering criteria based on the Euclidean distance–in accord to the standard Voronoi tes-
sellation definition- and maximum and minimum distances have been considered.
To interpret the outcomes of the analysis, we need to provide an intuitie description of the
clustering criteria.
The minimum distance is the one that underestimate the toxicity level, in that it may place
a drug in a low-toxicity cluster even if some related parameters are of remarkable high level.
Differently, the maximum distance is more “cautios” and overestimates the level of toxicity,
since it may insert an agent into a high-toxicity cluster even when some toxicity parameters
exhibit a low value.
The “fair” situation is captured by the Euclidean distance, which is the one used in the origi-
nal Voronoi model. The comparison among the results of the clustering proedures suggests
that taking a definition of toxicity that may imply its overestimation is closer to fairness than
dealing with an understimation criterion.
It is important to note that the toxicity associated with oncological drugs implicates a high-
cost management. In this regard, previous studies have tried to quantify this amount. For
example, Roncato et al. [64] evaluated the economic burden of Irinotecan-related toxicity in
patients with metastatic colorectal cancer, revealing that the mean predicted cost per patient
Fig 3. Voronoi tesselation based on Toxicity Index (TI) considering Euclidean distance.
https://doi.org/10.1371/journal.pone.0183639.g003
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was 4,886 €. On the other hand, Arondekar et al. [65] investigated the costs of AEs in 2,621
patients with metastatic melanoma by employing multivariate generalized linear models
(GLMs) with a log-link function and gamma distribution. They reported a 30-day incremental
cost of over 9,000 $ for metabolic AEs, 8,450 $ for hematologic, 6,476 $ for cardiovascular and
6,338 $ for gastrointestinal AEs [65].
Similarly, Bilir et al. [66] studied the economic burden of toxicities associated with treating
metastatic melanoma in the United States. They registered that the highest mean in patient
costs for an AE were associated with acute myocardial infarction, sepsis, and coma, ranging
Table 3. List of target agents approved for their use in cancer patients and related costs. BCC = Basal-cell Carcinoma; GIST = Gastrointestinal Stro-
mal Tumor; NSCLC = Non Small Cell Lung Cancer; RCC = Renal Cell Carcinoma.
Target Agent Cancer Type Monthly cost ($) Cost per PFS ($)
Abiraterone acetate (first line therapy) Prostate 8,627 142,346
Abiraterone acetate (successive line-therapy) Prostate 8,627 48,311
Afatinib NSCLC 6,970 77,367
Bevacizumab Glioblastoma 4,400 24,640
Bevacizumab RCC 4,400 44,880
Bevacizumab (first line therapy) Colorectal 2,680 28,408
Bevacizumab (successive line-therapy) Colorectal 2,680 15,276
Cabozantinib Thyroid 14,300 160,160
Cetuximab Head and Neck 7,000 38,500
Cobimetinib + Vemurafenib Melanoma 26,300 260,370
Crizotinib NSCLC 11,500 88,550
Enzalutamide (first line therapy) Prostate 7,450 61,835
Enzalutamide (successive line-therapy) Prostate 7,450 42,465
Erlotinib Pancreas 2,450 9,310
Erlotinib (first line thrapy) NSCLC 3,000 29,100
Erlotinib (maintainance therapy) NSCLC 3,000 8,700
Everolimus Breast 7,000 54,600
Lenvatinib Thyroid 13,945 204,992
Nivolumab Squamous NSCLC 12,600 44,100
Nivolumab Non-Squamous NSCLC 12,600 28,980
Nivolumab Melanoma 12,600 64,260
Nivolumab RCC 6,984 32,126
Palbociclib (+letrozole) Breast 9,850 198,970
Palbociclib (+fulvestrant) Breast 9,850 90,620
Pembrolizumab Melanoma 23,017 94,370
Ramucirumab Gastric 13,000 27,300
Ramucirumab NSCLC 11,000 49,500
Ramucirumab Colorectal 13,000 74,100
Regorafenib Colorectal 7,600 14,440
Sonidegib BCC 12,000 157,200
Sorafenib RCC 6,600 36,300
Sunitinib RCC 7,000 77,000
Sunitinib GIST 7,000 44,800
T-DM1 Breast 9,800 94,080
Temsirolimus RCC 2,960 11,248
Trametinib + Dabrafenib Melanoma 16,300 151,590
Ziv-Aflibercept Colorectal 11,000 75,900
https://doi.org/10.1371/journal.pone.0183639.t003
Toxicity and cost of oncological target agents
PLOS ONE | https://doi.org/10.1371/journal.pone.0183639 August 22, 2017 10 / 17
from 31,682 $ to 47,069 $. In addition, the mean cost for hospitalization due to other AEs ran-
ged from 19,122 $ to 26,861 $ [66].
The quantification of the economic impact related to the toxicity of target agents will repre-
sent a major step forward in the phases of drug approval and cost establishement, representing
a fundamental parameter that must be considered during these processes.
In the last years, several techniques of drug reimboursement have been introduced in the
pharmacoeconomic scenario and are currently employed in the oncological field. These
modalities include: (1) payment by results, which consists in the total refund by the manyfac-
turer for non-responding patients; (2) risk sharing, which provides for a partial refund for
Fig 4. Cluster analysis based on Euclidean distance considering the drug costs for 1-month (A) or for the
median total duration of therapy (B) for a single oncological patient. Green points represent drugs with low
cost (Group A), violet points drugs with medium cost (Group B) and pink with high cost for 1-month of
treatment (Group C).
https://doi.org/10.1371/journal.pone.0183639.g004
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non-responding patients after a clinical/radiological evalutation; (3) cost sharing, which sets
an initial discount for all treated patients. These techniques have become even more funda-
mental after the introduction of immunotherapy in the therapeutic armamentarium of cancer
patients. In fact, these agents are characterized by both relevant cost and high efficacy, support-
ing the research for new tools aimed to optimize the use of economic resources in the health
system. In this respect, Russi et al. [67] proposed a new cost-containmet strategy for the use of
immunotherapic agent ipilimumab for patients with melanoma in Italy. This model included,
by one side, drug-day and centralization of compounding (accounting for a reduction of
-11.1% of drug cost) and, by the other side, payback systems designed by AIFA (resulting in
additional -6.2%) [67].
Our study present several limitations. First of all it is a systematic review realized starting
from clinical trials and not from individual patients’ data. Thus, data on drug toxicity might be
influenced by confounding factors such as the presence of different tumors, patients’ comor-
bidities or simultaneous treatments. Furthermore, patients eligible for clinical trials mostly
show fair organ functions, leading to a potential underestimation of drug toxicity compared to
clinical practice. Finally, we are awared that the various toxicities considered in our analysis
may have a different impact on patient QoL and a wide range of clinical consequences,
although we considered only SAEs that lead to patient hospitalization and/or medical inter-
ventions and the D rate.
In face of these limitations, at a macroscopic level, our analysis highlights that there is a not
straightforward relationship between the toxicity of target agents and their relative costs for
1-month or the whole treatment duration. However, we can notice that the number of target
agents with high costs results more relevant in the clusters associated with the worst drug-tol-
erability (high SAE and D rates), although they belong also to the cluster characterized by bet-
ter safety (low SAE and D rates).
Table 4. Distribution of costs within the 5 clusters based on TI.
1-month treatment cost Total cost for a single patient (estimated by PFS)
Group A (%) Group B (%) Group C (%) Group D (%) Group E (%) Group F (%)
Cluster 1 33 33 34 44 44 12
Cluster 2 22 34 44 11 56 33
Cluster 3 50 50 0 25 50 25
Cluster 4 38 24 38 63 0 37
Cluster 5 14 28 58 29 29 42
https://doi.org/10.1371/journal.pone.0183639.t004
Fig 5. The distribution of different clusters into the three cost categories related to the amount for median Progression-Free Survival (PFS).
https://doi.org/10.1371/journal.pone.0183639.g005
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Interestingly, data on kurtosis and skewness underline that a high percentage of cancer
patients treated with molecularly target agents do experience at least one all grade adverse
event. The toxicity of these drugs, altough lower than that associated with chemotherapy, sug-
gest that the costs of management of adverse events must be considered during the phases of
approval and price negotiation.
To sum up, the relationship between the cost and the efficacy and toxicity of new genera-
tion drugs does not follows a regular path. However, the constructed database and the findings
here obtained can be efficiently used for the development of a unified theory on the cost man-
agement of treating cancer patients and on the study of the impact of these agents on their
QoL.
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